Skip to main content
. 2014 Jan 28;8:235–241. doi: 10.2147/OPTH.S54578

Figure 1.

Figure 1

Changes in BCVA in the combined IVR with RF-PDT and the monotherapy IVR group. There was no significant difference in BCVA between the two groups at 12 months (P=0.546).

Note: *P<0.05.

Abbreviations: BCVA, best corrected visual acuity; IVR, intravitreal ranibizumab; logMAR, logarithm of the minimum angle of resolution; RF-PDT, reduced-fluence photodynamic therapy.